In contrast, other hypoglycemic drugs like dipeptidyl peptidase-4 inhibitors (DDP4i) and thiazolidinediones are ineffective in cardiovascular risk reduction and are even associated with increased heart failure in patients with type 2 diabetes mellitus (T2DM). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.